A Phase II Study of MK0683 in Patients With Relapsed / Refractory Follicular Lymphoma (FL), Other Indolent B-Cell Non-Hodgkin's Lymphoma (B-NHL) or Mantle Cell Lymphoma (MCL).

Trial Profile

A Phase II Study of MK0683 in Patients With Relapsed / Refractory Follicular Lymphoma (FL), Other Indolent B-Cell Non-Hodgkin's Lymphoma (B-NHL) or Mantle Cell Lymphoma (MCL).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Vorinostat (Primary)
  • Indications B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 13 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018.
    • 07 Feb 2014 Planned End Date changed from 1 Jan 2014 to 1 Jan 2017, as per ClinicalTrials.gov record.
    • 27 May 2011 Planned end date changed from 1 Jan 2011 to 1 Jan 2014 as reported by ClinicalTrials.gov..
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top